Responses to immune checkpoint
inhibitors in nonagenarians. Johnpulle,
Conry, Sosman, et al. Oncoimmunology. 2016 Oct 18.
The incidence of melanoma continues to rise with the most rapid
increase seen in the elderly population. Historically, elderly
patients with advanced melanoma have had dismal clinical outcomes, in
part, due to distinct tumor biology, and often ineligibility for
effective therapies during their development. In addition, due to
relatively few geriatric patients being accrued to clinical trials of
novel immunotherapeutics, there is a paucity of data regarding their
safety and efficacy. Herein, we present the clinical course of three
consecutive nonagenarians (more than or = to 90 y old) with
metastatic melanoma, who were treated with single-agent or
combination immune checkpoint inhibitors. Two patients experienced
complete or partial responses with acceptable safety profiles, and
one other tolerated therapy well although a significant response was
not noted. These cases suggest that with close monitoring, even very
elderly patients with advanced cancers and acceptable performance
status may tolerate and benefit from immune checkpoint inhibitors.
Good to know there is hope for all.... - c
No comments:
Post a Comment